https://www.sciencedirect.com/science/article/pii/S1568163726001686
There was a paper in 2024 that blamed HGPS on the mislocation of p300 (a HAT/KAT). I don’t think the authors of this paper have taken that into account.
chatGPT:
Summary
This is a narrative review on human longevity that frames ageing as a continuum between two extremes:
- Accelerated ageing, represented by progeroid and premature-ageing disorders such as Hutchinson–Gilford progeria, Werner syndrome, Cockayne syndrome and Down syndrome.
- Successful ageing, represented by centenarians, supercentenarians, long-lived species and protective genetic variants.
The central idea is a “genetic dichotomy”: damaging variants push shared ageing pathways toward instability and decline, while protective variants push some of the same pathways toward resilience, repair and homeostasis. The paper explicitly says this dichotomy helps explain ageing trajectories but does not deterministically predict them, because environment, stochastic damage, epigenetics and lifestyle also matter.
The main pathways discussed are:
- Genome maintenance and DNA repair: HGPS, Werner and Cockayne syndromes show how defects in nuclear lamina integrity, helicase function, transcription-coupled DNA repair and chromatin maintenance can produce accelerated degeneration.
- Chromatin and transcriptional regulation: the review treats chromatin structure, histone modification, transcriptional stability and epigenetic drift as central nodes linking progeroid disease and normal ageing.
- Mitochondrial function and redox balance: mitochondrial dysfunction is repeatedly presented as a convergent feature of accelerated ageing and as a target of longevity-associated resilience.
- Nutrient sensing and metabolic control: insulin/IGF-1, mTOR, AMPK, NAD⁺/sirtuin biology and caloric-restriction-like pathways are treated as conserved lifespan-regulating mechanisms.
- Autophagy and proteostasis: the paper gives weight to autophagy as a maintenance system, including genes such as MYTHO and pathways identified in worms, flies and other model systems.
- Inflammageing and senescence: chronic inflammation and persistent senescent cells are treated as drivers of age-related dysfunction, but the authors also recognise that senescence can be useful in wound repair and tumour suppression.
The review highlights several longevity-associated genes and variants, including FOXO3, APOE, SIRT6, BPIFB4/LAV-BPIFB4, CISD2 and MYTHO. It argues that these genes map onto conserved stress-response, metabolic, vascular, immune, mitochondrial and genome-stability pathways. FOXO3 and APOE are presented as the most robust human longevity loci, while SIRT6, BPIFB4, CISD2 and MYTHO are used as examples where mechanistic or functional evidence strengthens biological plausibility.
The figures and tables reinforce this structure. Figure 1 / Table 1 on page 4 contrasts accelerated ageing disorders with long-lived species and experimental models, and lists HGPS, Werner, Cockayne and Down syndrome with their causal genes and ageing-related phenotypes. Figure 2 on page 9 compares short-lived ageing models—yeast, worms, flies and killifish—and shows conserved longevity mechanisms such as caloric restriction, sirtuin biology, insulin/IGF signalling, AMPK, TOR/autophagy and C/EBPα isoform regulation.
The paper also reviews epigenetic clocks. It treats them as useful quantitative readouts of biological ageing, but warns that a fall in DNA methylation age after an intervention does not necessarily prove clinical benefit. It may reflect transient adaptation, technical variation, tissue composition changes or molecular shifts not yet linked to lower disease risk or mortality.
Finally, it discusses translational interventions: senolytics, senomorphics, rapamycin/metformin-like nutrient-sensing interventions, gene therapy, genome editing and biomarker-guided geroscience. The paper is cautious: it says interventions must be context-specific because senescent cells and stress responses can be harmful in chronic ageing but useful in acute repair, tumour suppression or physiological adaptation.
Novelty
The novelty is not that any single pathway is newly discovered. Most components—FOXO3, APOE, SIRT6, progeroid syndromes, senescence, mTOR, AMPK, autophagy, epigenetic clocks—are well-established.
The novelty lies more in the integrative framework:
-
Accelerated and successful ageing are treated as opposing “stress tests” of the same biological systems.
The paper argues that progeroid syndromes and centenarian genetics should be analysed together, because both reveal pressure points in genome maintenance, metabolism, stress response, inflammation and chromatin regulation. -
It tries to separate association, mechanism and translation.
This is useful because longevity genetics often overstates weak associations. The authors repeatedly note that common longevity variants usually have modest effect sizes, and that model-organism lifespan extension cannot be directly extrapolated to humans. -
It gives epigenetic clocks a role inside the dichotomy framework.
Rather than treating clocks simply as biomarkers, the review suggests they may quantify divergent ageing trajectories: acceleration in progeroid or pathological ageing versus relative resilience in successful ageing. -
It links the framework to intervention timing.
In accelerated ageing, therapies are framed as early rescue strategies; in ordinary ageing, the same classes of interventions may need to be preventive, intermittent or later-life targeted. -
It includes less commonly discussed longevity genes.
The inclusion of BPIFB4/LAV-BPIFB4, CISD2 and MYTHO alongside FOXO3, APOE and SIRT6 broadens the discussion beyond the usual ageing-review canon.
Critique
The paper is a useful, wide-ranging synthesis, but its central framework is more conceptual than evidentially decisive.
The strongest aspect is that it avoids claiming that ageing is genetically predetermined. It correctly emphasises polygenicity, environmental influence, weak effect sizes for most common variants, survival bias in centenarian cohorts and the limited translatability of animal models. That makes it more balanced than many longevity reviews.
However, there are several weaknesses.
First, the “genetic dichotomy” may be a little too neat. Progeroid syndromes are usually caused by rare, high-impact mutations with severe developmental and tissue-specific effects. Centenarian longevity is polygenic, probabilistic and heavily confounded by environment, cohort effects, healthcare access, infection history, diet and survivor selection. These are not truly symmetrical opposites.
Second, accelerated-ageing syndromes are partial models of ageing, not compressed versions of normal ageing. HGPS is heavily vascular and nuclear-lamina centred; Cockayne syndrome is neurodevelopmental and DNA-repair centred but does not produce the full spectrum of ordinary ageing; Down syndrome includes dosage effects and developmental biology. The paper does acknowledge this, but still leans on them as ageing models.
Third, the paper’s evidence hierarchy is mixed. It combines human genetics, cell biology, animal models, candidate genes, GWAS, clocks and intervention trials. That breadth is useful, but it also makes the conclusions hard to test. Because it is a qualitative narrative review, there is no formal meta-analysis, systematic scoring of evidence quality, or quantitative estimate of how much each pathway contributes to human longevity.
Fourth, some convergence may be partly field-driven rather than biology-driven. Ageing research already focuses heavily on DNA damage, senescence, inflammation, mitochondrial dysfunction, mTOR, autophagy and epigenetics. Therefore, many studies will appear to “converge” on those pathways because those are the pathways most often measured. The authors note this problem, which is good, but it remains a major limitation.
Fifth, the translational section is cautious but still somewhat speculative. Senolytics, rapamycin, metformin, gene therapies and clock-guided interventions are promising, but human clinical evidence for broad healthspan extension remains limited. The paper’s own warning is important: changing an epigenetic clock or a molecular marker is not the same as improving frailty, disease incidence, function or survival.
Overall assessment
This is a strong review as a conceptual map of ageing genetics and molecular geroscience. Its best contribution is to frame accelerated ageing and exceptional longevity as two ends of a pathway-resilience spectrum.
Its main weakness is that the central “dichotomy” is more of a heuristic than a proven biological law. The paper is most convincing when it identifies shared stress-response and maintenance pathways; it is less convincing if read as implying that centenarian biology can simply reverse progeroid mechanisms.
For your interests, the most relevant part is that the review gives considerable weight to chromatin regulation, transcriptional stability, mitochondrial function, autophagy and metabolic reprogramming—all of which fit with your broader acetyl-CoA / histone acetylation / splicing-fidelity ageing model.